OF
COGT icon

Optimize Financial’s Cogent Biosciences COGT Stock Holding History

Optimize Financial’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,024
Closed -$1.17M – 333
2025
Q4 		$1.17M Buy
33,024
+472
+1% +$13.3K 0.59% 40
2025
Q3 		$467K Buy
+32,552
New +$386K 0.24% 132
2025
Q1 		– Sell
-20,186
Closed -$157K – 237
2024
Q4 		$157K Buy
+20,186
New +$201K 0.12% 221

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Optimize Financial's COGT Position: Q1 2026 in Review

Optimize Financial sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 33,024 shares — an estimated $1.17M sold.

Optimize Financial first reported a position in COGT in Q4 2024 and held it in 3 quarters. The position peaked at $1.17M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Optimize Financial reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
  • Optimize Financial sold 33,024 Cogent Biosciences shares in Q1 2026, an estimated $1.17M.
  • Optimize Financial first reported a position in Cogent Biosciences in Q4 2024 and held it in 3 quarters.
  • Optimize Financial's Cogent Biosciences position peaked at $1.17M in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Optimize Financial's 13F filing for Q1 2026, filed 12 May 2026.